Leerink sees life-science tools benefiting from Anthropic's push into biology

** Leerink Partners says Anthropic's growing focus on biology could boost demand for laboratory automation, experiments and large-scale data needed to validate AI predictions

** Brokerage sees biotech firm Twist Bioscience TWST.O as the "single most important beneficiary", citing demand for synthetic DNA used to turn AI-designed proteins into testable molecules

** Says Anthropic is funding laboratory testing of 5,000 protein designs using Twist's synthetic DNA, highlighting the company's role in AI-driven drug discovery

** Leerink says Anthropic's Claude analyzed complex laboratory data in 19-23 minutes, potentially allowing researchers to move more quickly to subsequent experiments

** Brokerage says early protein-design results are promising, but more data and lab testing will be needed to develop formats suitable for medicines